Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of MK-7009 with pegylated interferon and ribavirin in chronic genotype 1 hepatitis C
2008-000150-12Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of vaniprevir in hepatitis C virus infection (5 arms), sponsored by Merck & Co. Primary endpoint: Sustained viral response at 24 weeks after end of treatment. Started Apr 2008; status: completed.
02
Drugs
vaniprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2008-000150-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000150-12.